SENSEX NIFTY
Ranbaxy Laboratories

News from other websites on Ranbaxy Laboratories

Sun Pharma reports Q4 net profit at Rs 888 cr, Ranbaxy deal shrinks earnings

May 29, 2015 at 19:41 | Source: FirstPost

New Delhi: Sun Pharma today reported a consolidated net profit of Rs 888.05 crore for the fourth quarter ended 31 March 2015.The company had posted a net profit of Rs 1,587.12 crore for the same period of the previous fiscal.Net sales of the company ...

Daiichi Sankyo's misery ends, block deal to give company coup de grce

Apr 22, 2015 at 14:21 | Source: FirstPost

The Japanese drug major, Daiichi Sankyo, has madeamends for the huge mistake it committed in 2008 when it bought itself into the Indian generic drug manufacturer Ranbaxy Laboratories Ltd for a whopping $3.2 billion.The Singh brothers got the lions sh...

Daiichi Sankyo's misery ends, block deal to give co final coup de grce

Apr 22, 2015 at 12:58 | Source: FirstPost

The Japanese drug major, Daiichi Sankyo, has madeamends for the huge mistake it committed in 2008 when it bought itself into the Indian generic drug manufacturer Ranbaxy Laboratories Ltd for a whopping $3.2 billion.The Singh brothers got the lions sh...

Daiichi Sankyo's misery ends, block deal gives co the final coup de grce

Apr 22, 2015 at 11:07 | Source: FirstPost

The Japanese drug major, Daiichi Sankyo, has madeamends for the huge mistake it committed in 2008 when it bought itself into the Indian generic drug manufacturer Ranbaxy Laboratories Ltd for a whopping $3.2 billion.The Singh brothers got the lions sh...

Daiichi Sankyo to exit Sun Pharma, sell its 9% stake for up to Rs 22,000 cr

Apr 21, 2015 at 08:45 | Source: FirstPost

Mumbai - Japan's Daiichi Sankyo Company Ltd is selling shares worth up to $3.6 billion or Rs 22,000 crore in Sun Pharmaceutical Industries Ltd, setting it on course to retreat from India after a roller-coaster seven years.Daiichi Sankyo bought India'...

Daiichi Sankyo to exit Sun Pharma, sell up its 9% stake for up to Rs 22,000 cr

Apr 21, 2015 at 08:45 | Source: FirstPost

Mumbai - Japan's Daiichi Sankyo Company Ltd is selling shares worth up to $3.6 billion or Rs 22,000 crore in Sun Pharmaceutical Industries Ltd, setting it on course to retreat from India after a roller-coaster seven years.Daiichi Sankyo bought India'...

Japan's Daiichi Sankyo to exit Sun Pharma, sell up to $3.6 bn stake

Apr 21, 2015 at 00:00 | Source: FirstPost

Mumbai - Japan's Daiichi Sankyo Company Ltd is selling shares worth up to $3.6 billion in Sun Pharmaceutical Industries Ltd, setting it on course to retreat from India after a roller-coaster seven years.Daiichi Sankyo bought India's Ranbaxy Laborator...

Sun Pharma open to large acquisitions post Ranbaxy

Mar 25, 2015 at 23:30 | Source: FirstPost

MUMBAI (Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd will look at making more large acquisitions even as it winds up a $3.2 billion deal to buy smaller rival Ranbaxy Laboratories Ltd.The Ranbaxy deal, which closed on Tuesday...

Sensex edges down in cautious trade, Sun Pharma rises

Mar 25, 2015 at 15:06 | Source: FirstPost

Mumbai: The BSE Sensex and Nifty edged down on Wednesday to their near six-week lows and were heading for a sixth straight session of falls, as caution ahead of the expiry of monthly derivatives and the end of the fiscal year hit blue-chips such as L...

Sun Pharma gets RBI nod for transfer of Ranbaxy overseas investments

Mar 24, 2015 at 13:42 | Source: FirstPost

New Delhi: Sun Pharmaceutical Industries has received RBI nod for transfer of overseas investments of Ranbaxy to it and issue its shares to the non-resident shareholders of the latter as part of their $4 billion merger deal.In a filing to the BSE, Ra...

Sun Pharma third-quarter profit falls

Feb 14, 2015 at 21:30 | Source: FirstPost

MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker, said on Saturday third-quarter net profit fell unexpectedly due to a decline in sales in the United States and costs from resolving regulatory issues at a manufacturing ...

US Federal Trade Commission approves Sun Pharma's Ranbaxy acquisition

Feb 02, 2015 at 12:42 | Source: FirstPost

New Delhi: The US Federal Trade Commission (FTC) has completed its review of the proposed USD 4 billion acquisition of Ranbaxy Laboratories by Sun Pharma and granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improv...

Ipca hit by FDA ban over Ratlam plant production violations

Jan 25, 2015 at 00:15 | Source: FirstPost

MUMBAI (Reuters) - U.S. regulator the Food and Drug Administration has banned imports from a Madhya Pradesh manufacturing plant of generic drugmaker Ipca Laboratories Ltd(IPCA.NS), citing violations of standard production practices.India is second on...

Ipca Labs hit by FDA ban on MP plant for standard violations

Jan 23, 2015 at 11:54 | Source: FirstPost

The US Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Ipca Laboratories Ltd's plant at Ratlam in Madhya Pradesh due to violations of standard production practices.Ipca had voluntarily halted shipments to the Unite...

US Court Denies Ranbaxy's Bid to Block Launch of Rival Generics

Nov 20, 2014 at 22:00 | Source: NDTV Profit

A US court has denied a request by drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit again...

Ranbaxy to Exit Nifty Junior Index From November 28

Nov 19, 2014 at 02:00 | Source: NDTV Profit

Mumbai: Drug maker Ranbaxy Laboratories is being moved out of the National Stock Exchange's CNX Nifty Junior index and would be replaced by Reliance Infrastructure. The changes have been made on "account of proposed scheme of amalgam...

Ranbaxy sues US drug regulator over revoking approvals

Nov 18, 2014 at 20:00 | Source: VC Circle

Early this month FDA revoked tentative approval to Ranbaxy for selling low-cost versions of Nexium and Valcyte. Daiichi Sankyo-controlled Ranbaxy Laboratories has sued the US Federal Drug Authority (FDA) for revoking approvals granted to it to launch...

USFDA revokes Ranbaxy&#39;s approval to sell generic versions of Nexium and <b>...</b>

Nov 07, 2014 at 16:00 | Source: VC Circle

The American drug regulator has revoked Ranbaxy Laboratories&#39; tentative approval for selling copy cat low cost versions of blockbuster heartburn drug Nexium and anti-viral drug Valcyte in the world&#39;s largest drug market. USFDA said it...

Double blow to Ranbaxy

Nov 07, 2014 at 12:42 | Source: Calcutta Telegraph News

Mumbai, Nov. 6: The US health regulator has revoked tentative approvals to Ranbaxy Laboratories to make the generic versions of AstraZeneca’s heartburn drug Nexium and Roche Holding’s anti-viral Valcyte. The tentative approvals to the tw...

Ranbaxy Shares Fall 5% on US FDA Blow

Nov 07, 2014 at 10:00 | Source: NDTV Profit

Shares in Ranbaxy fell over 5 per cent to a day low of Rs 618.85 in the opening session on Friday after the US Food and Drug Administration (FDA) revoked a tentative approval for Ranbaxy Laboratories two drugs. The US FDA has withdrawn its approval f...

video of the day

See 33,000 Sensex by Dec; like cement, engg, oil: Deutsche

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.